Hospital stocks: Margins hit 22% in FY24, demand gap

Hospital stocks have re-rated since 2019

Hospital stocks have drawn fresh investor attention after a shift from high-debt balance sheets to stronger profitability since 2019. A video discussion on the sector attributes the change to a combination of operating improvements and structural demand tailwinds. The key headline metric is margin expansion, with the sector’s operating margin cited at 14% in FY19 and 22% in FY24. The same discussion frames hospitals less as cyclical businesses and more as long-duration compounding stories, backed by capacity constraints and steady pricing. It also points to industry revenue growth expectations of 16% to 18% as a critical assumption for sustaining returns. While stock-specific outcomes vary, the broader re-rating has coincided with visible outperformance in parts of the listed healthcare pack.

The “big shift” in profitability: FY19 to FY24

The pre-2019 period is described as one where hospital companies struggled with interest payments, implying elevated leverage and weaker cash flows. The improvement is quantified through operating margins moving from 14% in FY19 to 22% by FY24. The outlook presented for the near term is for operating margins to remain stable in a 22% to 24% range, rather than revert to earlier lows. The discussion also highlights ARPOB (average revenue per occupied bed) as a key metric expected to grow steadily, alongside stable margins. These metrics matter because they capture both utilisation and pricing power, which typically drive operating leverage in hospital models. In market narratives, the combination of higher margins and stable demand has been a core argument behind multiyear stock price compounding in select names.

Demand-supply gap: India’s bed shortage remains large

A central driver cited is the structural gap between demand and supply in hospital infrastructure. India is stated to have 1.3 hospital beds for every 1,000 people versus a global average of 3 beds per 1,000. This implies India is at less than half the global average on this measure. The discussion quantifies the shortfall at about 2.4 million beds across the country. Such a gap can support sustained occupancy and pricing across organised providers, especially in higher-acuity segments. The same narrative suggests the runway is amplified by demographic and epidemiological shifts, which tend to increase healthcare utilisation over time.

Insurance, ageing and chronic diseases as demand catalysts

Beyond infrastructure constraints, the video points to multiple demand accelerators. India’s population ageing trend is referenced as a factor that typically increases hospitalisation intensity and frequency. Chronic diseases are described as rising, which often results in recurring care pathways and higher case complexity. Another cited driver is expanding health insurance coverage, which can broaden affordability and shift care from informal settings to organised hospitals. Together, these forces are positioned as supporting steady patient inflows rather than one-off surges. The discussion presents demand growth as “settled” compared with supply creation, which is inherently slower due to capital intensity.

Medical tourism adds a high-margin layer

Medical tourism is highlighted as another contributor, particularly for complex and higher-margin procedures. The cost differential is illustrated with a reference point of around $1,200 for a procedure in India, paired with a claim of comparable quality of care. The logic is that a material cost advantage can attract international patient volumes, and that these patients often seek specialised interventions. While the text does not quantify the share of revenues from medical tourism, it frames the segment as supportive of margin stability due to case mix. In hospital models, case mix improvement can lift ARPOB and reduce reliance on low-acuity volumes.

Conflicting healthcare market size projections to 2026

The provided material contains differing projections for India’s healthcare market size, and readers should note the inconsistency. One estimate says the market could surpass $110 billion by 2026, while separately stating a level of $170 billion in 2022 and a CAGR of about 22% since 2016. Another estimate says India’s healthcare market could exceed $110 billion by 2026, up from $170 billion in 2022. Both projections are presented as part of the broader “growth path” narrative that includes capacity expansion, rising insurance coverage, and strong pharmaceutical exports. Because the estimates conflict, they are best read as indicative of bullish expectations rather than a single agreed baseline.

FY25 performance: Healthcare index versus Sensex

In FY25 so far, the BSE Healthcare sector is cited as one of the top performers, gaining nearly 24% versus a 9% rise in the benchmark Sensex over the same period. Within this rally, multiple healthcare stocks are reported to have delivered more than 100% returns in FY25 to date, based on ACE Equity data. The list includes companies across hospitals, pharmaceuticals and life sciences, underscoring that the healthcare theme has been broad-based in the reported period. Still, the hospital segment’s margin narrative has been a distinct catalyst for investor interest since FY19.

Key numbers at a glance

Stock-specific moves mentioned in the data

Aayush Wellness Ltd, described as engaged in nutraceuticals, personalised healthcare, preventive wellness and digital health solutions, hit a 2% upper circuit after its board approved the launch of Brain Fuel Capsules. The stock moved to Rs 242.30 from a previous close of Rs 237.55, and the company’s market capitalisation is stated at Rs 1,156 crore. Separately, another healthcare stock (name not provided in the text) is described as opening about 2% lower at Rs 28.82 versus a previous close of Rs 29.40; its 52-week high and low are cited at Rs 53.50 and Rs 7.35, with a market cap of Rs 693.58. That same stock is said to have fallen for six days, down 11.3% over the period, while still showing multibagger returns of 295% in one year and 326% in two years, despite correcting over 35% so far this year.

Artemis Medicare Services is also cited as a recent multibagger example within hospital stocks. Its share price is described as rising about 1,000% in around 4.5 years, from Rs 22.60 to Rs 250 per share. On the day referenced, it opened at Rs 249 and touched Rs 259.90, about 5% higher than the previous close of Rs 246.75. The stock’s lifetime high is stated at Rs 270, and the text links buying interest to the release of Q1 2024 results.

FY25 multibaggers list: top eight healthcare stocks

Why the margin story matters for investors

The 14% to 22% margin expansion is significant because it suggests hospitals have improved operating leverage and cash generation versus the pre-FY19 backdrop described as interest-heavy. If margins hold in the 22% to 24% band as suggested, stock performance will likely hinge on sustaining volume growth and ARPOB expansion rather than balance-sheet repair alone. The demand-supply gap numbers (1.3 beds per 1,000 people in India versus 3 globally, and a 2.4 million bed shortfall) provide a structural explanation for why utilisation can remain supportive. At the same time, the stock examples show dispersion: some names see upper circuits on product launches, others face drawdowns even after strong longer-term returns. The FY25 rally data also indicates that the healthcare theme has extended beyond hospitals into pharma and life sciences.

Conclusion

The data presented frames hospital stocks as beneficiaries of a post-2019 profitability reset, highlighted by operating margins rising to 22% in FY24 from 14% in FY19. Structural demand drivers cited include a large bed shortfall, ageing trends, chronic disease prevalence, wider insurance coverage and medical tourism. Market attention in FY25 has also broadened to the wider healthcare universe, with the BSE Healthcare index up nearly 24% versus 9% for the Sensex and multiple stocks posting over 100% gains. The key variables to watch, based on the discussion, are whether industry revenue growth stays in the 16% to 18% range and whether operating margins remain stable in the 22% to 24% band.